Journal of liver cancer最新文献_第5页

Changing etiology and epidemiology of hepatocellular carcinoma: Asia and worldwide. 不断变化的肝细胞癌病因学和流行病学：亚洲和全球。

Journal of liver cancer Pub Date : 2024-03-01 Epub Date: 2024-03-25 DOI: 10.17998/jlc.2024.03.13

Do Young Kim

{"title":"Changing etiology and epidemiology of hepatocellular carcinoma: Asia and worldwide.","authors":"Do Young Kim","doi":"10.17998/jlc.2024.03.13","DOIUrl":"10.17998/jlc.2024.03.13","url":null,"abstract":"Approximately 80% of hepatocellular carcinoma (HCC) cases arise in sub-Saharan Africa and Eastern Asia, following a similarly high prevalence of chronic hepatitis B virus (HBV) carriers in these regions. The etiology and epidemiology of HCC have recently changed worldwide. Although HBV infection is the main contributor to HCC development, a slow but continuous decline in HBV infection rates has been reported since 1990. Owing to the widespread use of direct-acting antivirals, the incidence of hepatitis C virus-related HCC has remarkably decreased in Japan and European countries. In Korea, Taiwan, and Singapore, the incidence of HBV-related HCC has significantly decreased owing to vaccination against HBV. Globally, while HBV accounted for more than half of HCCs in 1990, this had decreased to 42% in 2019. In contrast, the proportion of patients with alcoholic- and nonalcoholic steatohepatitis (NASH) increased from 13% to 18% and from 5% to 6%, respectively. NASH-related HCC has characteristics that differ from those of virus-associated HCC. Compared with other etiologies, patients with NASHassociated HCC are older, have a higher body mass index, and have higher rates of type 2 diabetes mellitus, hypertension, hyperlipidemia, and cardiovascular disease. Nonalcoholic fatty liver disease (NAFLD)-associated HCC is also known to develop in the absence of cirrhosis, unlike alcohol-related and autoimmune liver diseases. Because patients with NAFLD usually have diabetes or obesity, surveying this population is challenging. Optimal selection of the target population and surveillance tools among patients with NAFLD needs to be determined.","PeriodicalId":94087,"journal":{"name":"Journal of liver cancer","volume":" ","pages":"62-70"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10990659/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140208732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Treatment options for solitary hepatocellular carcinoma ≤5 cm: surgery vs. ablation: a multicenter retrospective study. ≤5cm的孤立性肝细胞癌的治疗选择：手术与消融：一项多中心回顾性研究。

Journal of liver cancer Pub Date : 2024-03-01 Epub Date: 2023-11-06 DOI: 10.17998/jlc.2023.09.11

Kazuya Kariyama, Kazuhiro Nouso, Atsushi Hiraoka, Hidenori Toyoda, Toshifumi Tada, Kunihiko Tsuji, Toru Ishikawa, Takeshi Hatanaka, Ei Itobayashi, Koichi Takaguchi, Akemi Tsutsui, Atsushi Naganuma, Satoshi Yasuda, Satoru Kakizaki, Akiko Wakuta, Shohei Shiota, Masatoshi Kudo, Takashi Kumada

{"title":"Treatment options for solitary hepatocellular carcinoma ≤5 cm: surgery vs. ablation: a multicenter retrospective study.","authors":"Kazuya Kariyama, Kazuhiro Nouso, Atsushi Hiraoka, Hidenori Toyoda, Toshifumi Tada, Kunihiko Tsuji, Toru Ishikawa, Takeshi Hatanaka, Ei Itobayashi, Koichi Takaguchi, Akemi Tsutsui, Atsushi Naganuma, Satoshi Yasuda, Satoru Kakizaki, Akiko Wakuta, Shohei Shiota, Masatoshi Kudo, Takashi Kumada","doi":"10.17998/jlc.2023.09.11","DOIUrl":"10.17998/jlc.2023.09.11","url":null,"abstract":"Background/aim: The aim of this study was to compare the therapeutic efficacy of ablation and surgery in solitary hepatocellular carcinoma (HCC) measuring ≤5 cm with a large HCC cohort database.Methods: The study included consecutive 2,067 patients with solitary HCC who were treated with either ablation (n=1,248) or surgery (n=819). Th e patients were divided into three groups based on the tumor size and compared the outcomes of the two therapies using propensity score matching.Results: No significant difference in recurrence-free survival (RFS) or overall survival (OS) was found between surgery and ablation groups for tumors measuring ≤2 cm or >2 cm but ≤3 cm. For tumors measuring >3 cm but ≤5 cm, RFS was significantly better with surgery than with ablation (3.6 and 2.0 years, respectively, P=0.0297). However, no significant difference in OS was found between surgery and ablation in this group (6.7 and 6.0 years, respectively, P=0.668).Conclusion: The study suggests that surgery and ablation can be equally used as a treatment for solitary HCC no more than 3 cm in diameter. For HCCs measuring 3-5 cm, the OS was not different between therapies; thus, ablation and less invasive therapy can be considered a treatment option; however, special caution should be taken to prevent recurrence.","PeriodicalId":94087,"journal":{"name":"Journal of liver cancer","volume":" ","pages":"71-80"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10990662/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71490496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Metastatic papillary renal cell carcinoma with portal vein tumor thrombosis confirmed on blind liver biopsy. 肝盲活检证实转移性乳头状肾细胞癌伴门静脉肿瘤血栓形成。

Journal of liver cancer Pub Date : 2024-03-01 Epub Date: 2023-11-29 DOI: 10.17998/jlc.2023.11.05

Hun Kim, Tae Hoon Roh, Jun Seop Lee, Min Seong Kim, Beom Kyung Kim

引用次数: 0

Management of early-stage hepatocellular carcinoma: challenges and strategies for optimal outcomes. 早期肝细胞癌的治疗：最佳结果的挑战和策略。

Journal of liver cancer Pub Date : 2023-09-01 Epub Date: 2023-09-21 DOI: 10.17998/jlc.2023.08.27

Jae Hyun Yoon, Sung Kyu Choi

{"title":"Management of early-stage hepatocellular carcinoma: challenges and strategies for optimal outcomes.","authors":"Jae Hyun Yoon, Sung Kyu Choi","doi":"10.17998/jlc.2023.08.27","DOIUrl":"10.17998/jlc.2023.08.27","url":null,"abstract":"Although hepatocellular carcinoma (HCC) is associated with a poor prognosis, management of early-stage HCC is often successful with highly efficacious treatment modalities such as liver transplantation, surgical resection, and radiofrequency ablation. However, unfavorable clinical outcomes have been observed under certain circumstances, even after efficient treatment. Factors that predict unsuitable results after treatment include tumor markers, inflammatory markers, imaging findings reflecting tumor biology, specific outcome indicators for each treatment modality, liver functional reserve, and the technical feasibility of the treatment modalities. Various strategies may overcome these challenges, including the application of reinforced treatment indication criteria with predictive markers reflecting tumor biology, compensation for technical issues with up-to-date technologies, modification of treatment modalities, downstaging with locoregional therapies (such as transarterial chemotherapy or radiotherapy), and recently introduced combination immunotherapies. In this review, we discuss the challenges to achieving optimal outcomes in the management of early-stage HCC and suggest strategies to overcome these obstacles.","PeriodicalId":94087,"journal":{"name":"Journal of liver cancer","volume":"23 2","pages":"300-315"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b9/25/jlc-2023-08-27.PMC10565545.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41157743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Sonazoid contrast-enhanced ultrasonography for the diagnosis of hepatocellular carcinoma: strengths and shortcomings. 超声造影诊断肝细胞癌的优势与不足。

Journal of liver cancer Pub Date : 2023-09-01 Epub Date: 2023-09-20 DOI: 10.17998/jlc.2023.09.12

Sung Won Lee, Min Kyu Kang, Xiang Zhang

引用次数: 0

A multidisciplinary approach with immunotherapies for advanced hepatocellular carcinoma. 晚期肝细胞癌免疫治疗的多学科方法。

Journal of liver cancer Pub Date : 2023-09-01 Epub Date: 2023-09-22 DOI: 10.17998/jlc.2023.09.04

Yu Rim Lee

{"title":"A multidisciplinary approach with immunotherapies for advanced hepatocellular carcinoma.","authors":"Yu Rim Lee","doi":"10.17998/jlc.2023.09.04","DOIUrl":"10.17998/jlc.2023.09.04","url":null,"abstract":"Hepatocellular carcinoma (HCC) is a highly aggressive disease that is usually diagnosed at an advanced stage. Advanced HCC has limited treatment options and often has a poor prognosis. For the past decade, tyrosine kinase inhibitors have been the only treatments approved for advanced HCC that have shown overall survival (OS) benefits; however, but their clinical efficacy has been limited. Recent trials have demonstrated promising advancements in survival outcomes through immunotherapy-based treatments, such as combinations of immune checkpoint inhibitors (ICIs) with other ICIs, antiangiogenic drugs, and locoregional therapies. The atezolizumab-bevacizumab and durvalumab-tremelimumab (STRIDE) regimen has significantly improved survival rates as a first-line treatment and has become the new standard of care. Therefore, combined treatments for advanced HCC can result in better treatment outcomes owing to their synergistic effects, which requires a multidisciplinary approach. Ongoing studies are examining other therapeutic innovations that can improve disease control and OS rates. Despite improvements in the treatment of advanced HCC, further studies on the optimal treatment selection and sequences, biomarker identification, combination approaches with other therapies, and development of novel immunotherapy agents are required. This review presents the current treatment options and clinical data of the ICI-based combination immunotherapies for advanced HCC from a multidisciplinary perspective.","PeriodicalId":94087,"journal":{"name":"Journal of liver cancer","volume":"23 2","pages":"316-329"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a3/8c/jlc-2023-09-04.PMC10565553.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41165451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Isolation and characterization of cancer-associated fibroblasts in the tumor microenvironment of hepatocellular carcinoma 肝细胞癌肿瘤微环境中癌相关成纤维细胞的分离与表征

Journal of liver cancer Pub Date : 2023-06-12 DOI: 10.17998/jlc.2022.04.30

Kyoungdo Mun, Jiwon Han, Pureun Roh, Jonggeun Park, Gahee Kim, Wonhee Hur, Jeongwon Jang, Jongyoung Choi, Seungkew Yoon, Youngkyoung You, Hojoong Choi, Pilsoo Sung

引用次数: 0